Twist Bioscience prices upsized $300M public offering of common stock at $96/share

Twist Bioscience Corp

Offering of 3,125,000 shares at $96.00 per share; underwriters' option for 468,750 additional shares exercised in full.
Net proceeds expected to be approximately $327.1 million after underwriting discounts and expenses.
Offering upsized from originally proposed $250 million to $300 million; expected to close August 6, 2026.
Proceeds to fund R&D, manufacturing capacity expansion, product offerings, and working capital.
Joint book-running managers: Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.